MOLECULAR PATHOLOGY WORKING GROUP

ACTIVITIES OF THE GROUP IN 2016:

1.ACTIVE WORKING GROUPS:

-OECI-ESP Working Group on Next Generation Sequencing in Clinical Research. (A. Jung, G. Stanta) -ESP Pre-Analytical Tissue Condition Working Groups. (C. Marchiò)

-ESP - Heterogeneity, inter-WGs of ESP. (WG leaders)

-OECI-ESP Liquid Biopsy WG (I. Gut, G. Stanta)

-ESP – Proteomics SOPs in AT, in development. (K. Becker)

-ESP In-Situ Techniques, in development. (G. Stanta)

- Member of the Committee of CEN (European Committee for Standardization) for Molecular in-vitro diagnostic examinations - Specifications for pre-examination processes for fresh tissues, FFPE tissues, blood for DNA, RNA and proteins, technical specifications to ISO 15189. Giorgio Stanta is the liaison representative from ESP to CEN/TC 140.

2.OTHER ACTIVITIES CARRIED OUT IN 2016:

-11-13 May: organization and implementation of "EACR-OECI-ESP 6th EACR-OECI Joint Training Course Molecular Pathology approach to Cancer". The course was held in Amsterdam.

This course was an advanced course on Molecular Pathology of Cancer, with some of the most experienced scientists in the field. It was very successful and attracted participants not only from Europe.

-15 June: organization and implementation of OECI, ESP, BBMRI-ERIC, EuroCan Platform, IMPACTS Pathology day in Brussels, Belgium: "Clinical Research and Applied Oncology: an integrated and indissoluble process". During the meeting tumour heterogeneity was discussed as clonal and non-clonal evolution. Three round tables were also held, related to tumour heterogeneity and industry, heterogeneity and tissue biobanking, heterogeneity and different tumour types, similarities and differences.

-25-29 September: organization and implementation of ESP-IAP Congress, Cologne.

a. Symposium: "Tumour Heterogeneity: an update".

b. Short course: "Preanalytical conditions of tissues".

c. Long course: "Major Cancer Theranostics".

3.PROJECTS:

-Participation in the European project HERCULES (Comprehensive characterisation and effective combinatorial targeting of high-grade serous ovarian cancer via single-cell analysis)

Project financed by the European Commission – Horizon 2020 – Call: H2020-PHC-2015 – Topic: PHC-02-2015 – Type of action: RIA – Proposal number: 667403-2. Coordinator: Prof. Sampsa Hautaniemi, University of Helsinki.

New type of collaboration between basic/translational research and clinical research for rapid validation of new biomarkers and molecular targets.

-Participation in the European project SPIDIA4P (SPIDIA for Personalized Medicine - Standardisation of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine).

Project financed by the European Commission – Horizon 2020 – Call: H2020-SC1-2016-RTD – Activity: SC1-HCO-02-2016 – Funding scheme: CSA – Proposal number: 733112. Coordinator: Qiagen GmbH, Hilden (Germany).